4 quarters tracked · Beat rate 50% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q2 2026 | 2026-03-31 | $-1.21 | $-0.93 | +23.2% | Beat |
| Q1 2026 | 2025-12-31 | $0.26 | $0.22 | -14.8% | Miss |
| Q4 2025 | 2025-09-30 | $-0.25 | $-0.18 | +26.7% | Beat |
| Q3 2025 | 2025-06-30 | $-1.05 | $-1.26 | -20.5% | Miss |
Earnings Beat Rate
Arrowhead Pharmaceuticals has beaten analyst EPS estimates in 2 of 4 tracked quarters (50% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →